Welcome to our dedicated page for Avalo Therapeutics news (Ticker: AVTX), a resource for investors and traders seeking the latest updates and insights on Avalo Therapeutics stock.
Avalo Therapeutics Inc (AVTX) is a clinical-stage biotechnology company pioneering therapies for immune dysregulation and inflammatory diseases. This dedicated news hub provides investors and industry professionals with timely updates on the company’s scientific advancements, regulatory milestones, and strategic developments.
Discover official press releases, clinical trial progress, and partnership announcements related to AVTX’s innovative pipeline – including its lead asset AVTX-009 and other biologics targeting critical immune pathways. Our curated collection ensures transparent access to essential updates without speculative commentary.
Key content categories include:
• Clinical trial results and regulatory submissions
• Research collaborations and licensing agreements
• Financial reporting and corporate communications
• Scientific presentations and peer-reviewed publications
Bookmark this page for streamlined tracking of Avalo’s progress in developing targeted therapies for complex inflammatory conditions. Check regularly for authoritative updates directly from company sources and verified industry reports.
Avalo Therapeutics (Nasdaq: AVTX) will hold a virtual Investor Day on January 6, 2022, from 8:00 a.m. to 10:00 a.m. ET. The event will feature presentations from key executives including CEO Michael Cola and CMO H. Jeffrey Wilkins, providing updates on their clinical pipeline. Key discussion points will include:
- Phase 1b study of AVTX-002 for Crohn’s disease, and plans for ulcerative colitis.
- Development updates for AVTX-007 targeting multiple myeloma.
- Progress on AVTX-803 for leukocyte adhesion deficiency type II.
- Overview of other pipeline programs and 2022 goals.
Avalo Therapeutics, Inc. (Nasdaq: AVTX) has appointed Dr. June Almenoff and Mitchell Chan as independent board members, effective November 10 and December 1, 2021, respectively. They replace Dr. Suzanne Bruhn and Philip Gutry. Dr. Almenoff brings nearly 25 years of biopharma leadership experience, while Mr. Chan has over 15 years of finance expertise in life sciences. CEO Mike Cola expressed confidence that their combined experience will support the company's strategic priorities for the upcoming year.
Avalo Therapeutics (Nasdaq: AVTX), a clinical-stage precision medicine company, announced that its senior management will present at two key healthcare conferences. The Stifel 2021 Virtual Healthcare Conference is set for November 17, 2021, at 4:00 PM ET, while the Jefferies 2021 London Healthcare Conference will take place from November 16-18, 2021, with a pre-recorded presentation available on November 18, 2021, at 8:00 AM GMT. Webcasts can be accessed through the company’s website.
Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced its financial results for Q3 2021, reporting cash and cash equivalents of $71.5 million. Following a successful public offering raising $31.5 million, Avalo continues to focus on pipeline development, with key data readouts anticipated in the coming months for multiple programs, notably AVTX-002 for Crohn's disease, expected in Q4 2021. The company also completed significant financing to support its operations and expansion into new therapeutic areas, including immuno-oncology and rare genetic diseases.
Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced that its senior management team will present at the Jefferies Next Generation IBD Therapeutics Summit on October 19, 2021. A pre-recorded webcast of the presentation will be available starting at 8:00 AM ET on the same day, accessible via the Investor section of the company's website. Avalo focuses on developing targeted therapeutics for unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases, aiming to deliver impactful medical solutions.
Horizon Technology Finance Corporation (NASDAQ: HRZN) reported strong performance for Q3 2021, achieving a record $141 million in loan originations, with $99 million attributed to HRZN. The portfolio ended with a committed backlog of $123 million, reflecting robust demand for venture loans. During the quarter, HRZN received $50 million in loan prepayments, boosting fee and interest income. The company closed new loan commitments totaling $91 million, with a significant pipeline of opportunities, suggesting ongoing growth potential for shareholders.
Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced that its senior management will present in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference, scheduled for September 29, 2021, at 2:00 PM ET. This engaging session will provide insights into the company's precision medicine initiatives targeting unmet clinical needs in immunology and rare diseases. A live webcast will be available on the company's website under the 'News/Events' section.
Avalo Therapeutics (AVTX) has successfully closed its underwritten offering of common stock, selling a total of 14,308,878 shares at a public offering price of $2.20 each. This offering raised approximately $31.5 million in gross proceeds before expenses. The shares were sold under an effective registration statement with the SEC, and Jefferies and RBC Capital Markets acted as joint book-running managers for the offering. The funds will support Avalo's commitment to developing targeted therapeutics for patients with unmet medical needs.
Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced an underwriting agreement with Jefferies LLC and RBC Capital Markets for a public offering of 12,500,000 shares at $2.20 each, expected to close around September 17, 2021. If the underwriters exercise their option, total gross proceeds could reach approximately $31.6 million. The proceeds will be used for working capital and general corporate purposes. The offering is made under an effective shelf registration statement previously filed with the SEC.
Avalo Therapeutics (Nasdaq: AVTX) announced its intention to conduct an underwritten public offering of common stock, with a potential 30-day option for underwriters to purchase an additional 15%. The offering aims to raise funds for working capital and general corporate purposes, and will be executed under an effective shelf registration statement. Jefferies and RBC Capital Markets serve as joint book-running managers. The offering is subject to market conditions, with no guarantee of completion or specific terms.
FAQ
What is the current stock price of Avalo Therapeutics (AVTX)?
What is the market cap of Avalo Therapeutics (AVTX)?
